Microbial Disruption of Dendritic Cell Maturation and Function
树突状细胞成熟和功能的微生物破坏
基本信息
- 批准号:10468732
- 负责人:
- 金额:$ 58.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnaerobic BacteriaAntigen-Presenting CellsAntigensApolipoprotein EAreaAtherosclerosisAutoimmune DiseasesBacteriaBone DiseasesCardiovascular DiseasesCell MaturationCell physiologyCellsChronicClinicalDendritic CellsDetectionDevelopmentDiseaseEquilibriumExhibitsGram-Negative BacteriaGram-Negative Bacterial InfectionsHumanImmuneImmune EvasionImmune responseImmune signalingImmune systemImmunityImmunologic ReceptorsImmunologicsIn VitroInflammationInflammatoryLipid AMalignant NeoplasmsMeasuresMediatingModelingModificationMusMyelogenousNatural ImmunityNatureOralOral cavityOral mucous membrane structureOutcomeOvalbuminPathogenesisPathway interactionsPeriodontal DiseasesPersonsPhenotypePhosphoric Monoester HydrolasesPhosphorylationPlayPorphyromonas gingivalisRheumatoid ArthritisRiskRisk FactorsRoleSignal TransductionSiteT cell differentiationT cell responseT-Cell ActivationT-Cell Activation PathwayT-LymphocyteTLR2 geneTLR4 geneTestingTransgenic OrganismsUnited Statesadaptive immune responseadaptive immunityantagonistarmbasechronic infectionhuman pathogenimmunopathologyin vivoinsightmicrobialmonocytemutantnon-alcoholic fatty liver diseaseoral infectionpathogenpathogenic microbereceptorresponsesystemic inflammatory responsevascular inflammation
项目摘要
Several human pathogens express structurally divergent forms of lipid A, the biologically active moiety of LPS,
as a strategy to evade innate immune detection and establish chronic infection. The oral mucosal pathogen
Porphyromonas gingivalis intrinsically expresses underacylated lipid A moieties and can modify the
phosphorylation of lipid A, leading to altered TLR4 signaling. In addition to local immunopathology, significant
clinical and experimental evidence implicate P. gingivalis as risk factor for the development of chronic
systemic inflammatory diseases including rheumatoid arthritis, cancer, and cardiovascular disease.
Dysregulated T cell responses are believed to play a role in these inflammatory disorders. While the role of
lipid A modifications in evasion of innate immune signaling is established, how this influences adaptive immune
responses that contribute to dysregulation of host immunity has not been explored. Myeloid dendritic cells
(DCs) and their blood monocyte precursors play an important role in bridging the innate and adaptive arms of
the immune system during Gram-negative bacterial infection. TLR4 activation in these cells induces a distinct
maturation phenotype that promotes their mobilization to immune T cell areas for initiation of antigen-specific
immunity. Despite the wealth of studies on P. gingivalis pathogenesis in the oral cavity, the immunological
mechanisms underlying P. gingivalis mediated systemic inflammation are not well defined.
We propose in this application to define the impact of P. gingivalis lipid A moieties on DC responses and T cell
activation that contribute to P. gingivalis mediated systemic immunopathology. We hypothesize that the
different lipid A species expressed by P. gingivalis drive DC responses leading to distinct T cell activation
pathways that contribute to P. gingivalis-mediated systemic inflammatory outcomes. The following Aims are
proposed to test this hypothesis: Aim 1. To define the role of P. gingivalis lipid A species and TLR4 signaling
in DC responses and T cell activation in vitro. Aim 2.To define the role of P. gingivalis lipid A species on TLR4-
dependent DC and T cell responses following P. gingivalis oral infection. Aim 3. To define the role of P.
gingivalis distinct lipid A species and DC-specific TLR4 signaling in the development of P. gingivalis induced
immunopathology in vivo.
Strikingly, several Gram-negative bacteria that express immune-evasive lipid A are associated with increased
risk of autoimmune disease, atherosclerosis, and cancer. Thus, these studies have broad implications and will
provide important insights into the mechanisms by which Gram-negative pathogens alter systemic adaptive
immune responses resulting immunopathology.
!
几种人类病原体表达结构不同的A类脂蛋白,即内毒素的生物活性部分,
作为逃避先天免疫检测和确定慢性感染的一种策略。口腔粘膜病原体
牙龈卟啉单胞菌固有地表达低酰化的脂类A部分,并能改变
脂质A的磷酸化,导致TLR4信号的改变。除了局部免疫病理学,有意义的
临床和实验证据表明牙龈假单胞菌是慢性牙周炎发生的危险因素
全身性炎症性疾病,包括类风湿性关节炎、癌症和心血管疾病。
调节失调的T细胞反应被认为在这些炎症性疾病中发挥了作用。虽然这一角色
建立了逃避天然免疫信号的脂质A修饰,这如何影响获得性免疫
导致宿主免疫失调的反应还没有被探索。髓系树突状细胞
(DC)及其血液单核细胞前体在连接先天和适应性臂中发挥重要作用。
革兰氏阴性细菌感染时的免疫系统。这些细胞中TLR4的激活诱导了不同的
促进其动员到免疫T细胞区域以启动抗原特异性的成熟表型
豁免权。尽管关于牙龈假单胞菌在口腔中的致病机制的研究很丰富,但免疫学
牙龈假单胞菌介导的全身性炎症的机制尚不清楚。
在这项应用中,我们建议确定牙龈假单胞菌类脂A部分对DC反应和T细胞的影响
参与牙龈假单胞菌介导的全身免疫病理的激活。我们假设
牙龈假单胞菌表达的不同类脂A可驱动DC反应,导致不同的T细胞活化
促进牙龈假单胞菌介导的全身性炎症结果的途径。以下是目标
建议检验这一假说:目的1.明确牙龈假单胞菌脂类A种类和TLR4信号转导途径的作用
在DC应答和T细胞体外激活方面。目的2.明确牙龈假单胞菌类脂A对TLR4的作用。
口腔感染牙龈假单胞菌后依赖的DC和T细胞反应。目的3.明确P。
牙周炎不同类脂A及DC特异性TLR4信号在牙周炎致病中的作用
活体免疫病理学。
值得注意的是,几种表达免疫逃避类脂A的革兰氏阴性细菌与
自身免疫性疾病、动脉粥样硬化和癌症的风险。因此,这些研究具有广泛的影响,并将
对革兰氏阴性病原体改变全身适应性的机制提供了重要的见解
免疫反应导致的免疫病理学。
好了!
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Microbial Lipid A Remodeling Controls Cross-Presentation Efficiency and CD8 T Cell Priming by Modulating Dendritic Cell Function.
微生物脂质 A 重塑通过调节树突状细胞功能来控制交叉呈递效率和 CD8 T 细胞启动。
- DOI:10.1128/iai.00335-20
- 发表时间:2021
- 期刊:
- 影响因子:3.1
- 作者:Papadopoulos,George;Berland,Robert;Sunkavalli,Ashwini;Coats,StephenR;Darveau,RichardP;Genco,CarolineA
- 通讯作者:Genco,CarolineA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Caroline A Genco其他文献
Caroline A Genco的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Caroline A Genco', 18)}}的其他基金
Porphyromonas gingivalis and Pancreatic Carcinogenesis in Mouse Models
小鼠模型中牙龈卟啉单胞菌与胰腺癌发生
- 批准号:
9519194 - 财政年份:2018
- 资助金额:
$ 58.61万 - 项目类别:
Microbial Disruption of Dendritic Cell Maturation and Function
树突状细胞成熟和功能的微生物破坏
- 批准号:
10237941 - 财政年份:2018
- 资助金额:
$ 58.61万 - 项目类别:
Microbial Disruption of Dendritic Cell Maturation and Function
树突状细胞成熟和功能的微生物破坏
- 批准号:
9790936 - 财政年份:2018
- 资助金额:
$ 58.61万 - 项目类别:
The Gonococcal Fur Regulon Link to Pathogenesis
淋球菌毛皮调节子与发病机制的联系
- 批准号:
9751634 - 财政年份:2017
- 资助金额:
$ 58.61万 - 项目类别:
Global Transcriptome Analysis of Mucosal Gonoccal Infection
粘膜淋菌感染的全局转录组分析
- 批准号:
9333190 - 财政年份:2016
- 资助金额:
$ 58.61万 - 项目类别:
TLR4 evasion, bacterial persistence and chronic inflammation
TLR4 逃避、细菌持续存在和慢性炎症
- 批准号:
8926492 - 财政年份:2014
- 资助金额:
$ 58.61万 - 项目类别:
TLR4 evasion, bacterial persistence and chronic inflammation
TLR4 逃避、细菌持续存在和慢性炎症
- 批准号:
9117800 - 财政年份:2014
- 资助金额:
$ 58.61万 - 项目类别:
Global transcriptome analysis of mucosal gonococcal infection
粘膜淋球菌感染的全局转录组分析
- 批准号:
9101453 - 财政年份:2014
- 资助金额:
$ 58.61万 - 项目类别:
Global transcriptome analysis of mucosal gonococcal infection
粘膜淋球菌感染的全局转录组分析
- 批准号:
8889364 - 财政年份:2014
- 资助金额:
$ 58.61万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 58.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 58.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 58.61万 - 项目类别: